Vertex says combo of Roche drugs, telaprevir shows promise in study

04/27/2009 | Bloomberg

Vertex Pharmaceuticals announced that the combination of its hepatitis C drug telaprevir with Roche Holding's Pegasys and Copegus eradicated signs of the virus and elicited sustained response in 52% of patients, compared with 14% of those who received Roche's medicines alone. The yearlong study observed 453 patients who either relapsed after or failed to respond to previous hepatitis C therapies.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ